No IVAX/Noven deal
Executive Summary
IVAX will not proceed with $ 47 mil. pooling of interests acquisition of transdermal drug delivery R&D firm Noven Pharmaeuticals due to a determination that the deal "would not satisfy the requirement for a 'pooling of interests' accounting treatment," Ivax announces Oct. 23. The two Miami-based companies are, however, negotiating for "licensing and other business arrangements"....